WO2000069465A1 - Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif - Google Patents
Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif Download PDFInfo
- Publication number
- WO2000069465A1 WO2000069465A1 PCT/JP2000/003028 JP0003028W WO0069465A1 WO 2000069465 A1 WO2000069465 A1 WO 2000069465A1 JP 0003028 W JP0003028 W JP 0003028W WO 0069465 A1 WO0069465 A1 WO 0069465A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- alkyl
- cancer
- group
- hydrogen atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- EP 1 Anti-cancer agent containing an gonist as active ingredient
- the present invention relates to a therapeutic and / or prophylactic agent for cancer comprising an EP1 antagonist as an active ingredient.
- Cyclooxygenase is an enzyme that biosynthesizes prostaglandin H2, a precursor of various prostaglandins (hereinafter abbreviated as PG (s) or PGs (s)), from arachidonic acid. is there.
- PG prostaglandin H2
- PGs a precursor of various prostaglandins
- COX2 Two isozymes of cyclooxygenase are known, and the inducible form that is implicated in the inflammatory response is called COX2.
- COX2 is induced in various gastrointestinal tumor tissues of humans, rats and mice, and it has been reported that prostaglandins (particularly PGE 2) are contained in high concentrations (Narisawa T. et al. , et al. Dis. Colon. Rectum. 33, 840-845, 1990; Maxwell WJ et al., Digestion 47, 160-166, 1990).
- nonsteroidal anti-inflammatory drugs inhibit endogenous prostaglandin by inhibiting cyclooxygenase, especially COX2. It is thought to inhibit gin synthesis and suppress tumor cell growth and immune function.
- prostaglandin E 2 (abbreviated as PGE 2) is known as a metabolite in arachidonic acid reminder, and its effects are cytoprotection, uterine contraction, painful action, gastrointestinal peristalsis. It is known to have exercise-promoting, arousal, gastric acid secretion-suppressing, blood pressure-lowering, diuretic and other effects.
- PGE 2 has the disadvantage that its biological activity is so diverse that actions other than the desired action become side effects, but the role of each subtype is investigated to find compounds that are effective only for that subtype. Research continues to overcome this shortcoming.
- the EP1 subtype is known to be involved in pain, fever and diuresis (Br. J. Pharamacol., 1944, ⁇ 2, 735-40; European J. Pharmacol., 152 (1988) 273-279; Gen Pharmacol., Se1992, 23 (5) P805-8Q9). Therefore, antagonizing this receptor is considered to be effective as an analgesic, antipyretic, or therapeutic agent for pollakiuria.
- the present invention relates to a therapeutic and / or prophylactic agent for cancer, comprising an EP1 antagonist as an active ingredient.
- R 1A is hydroxy, C:!-4 alkoxy group or a general formula
- NR 6A R 7A (wherein, R 6A and R 7A each independently represent a hydrogen atom or a C 1-4 alkyl group.)
- R 2A represents a hydrogen atom or a C 1-4 alkyl group
- R 3A and R 4A represent a C 1-4 alkyl group, a halogen atom or a trifluoromethyl group
- R 5 A represents a hydrogen atom, a C 1-4 alkyl group, a halogen atom or a trifluoromethyl group
- Y represents cis-vinylene or trans-vinylene
- ⁇ Represents a single bond or a double bond.
- R 1B is a hydroxyl group, C 1-4 alkoxy or a formula
- Z 2 is a hydrogen atom, C 1-4 alkyl, C 1-4 alkoxy, nitro, halogen, trifluoromethyl, trifluoromethoxy, hydroxyl group or formula
- Z 3 represents a single bond or C 1-4 alkylene
- Z 4 represents SO 2 or CO
- the phenyl, C 3-7 cycloalkyl, 5 or 7 membered heterocycle having one or two oxygen, sulfur or nitrogen atoms in the above (2) and (3) is 1-5 R 5B Groups (a plurality of R 5B groups independently represent a hydrogen atom, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, nitro, halogen, trifluoromethyl, trifluoromethoxy or a hydroxyl group) May be replaced by.)
- R 8B represents a hydrogen atom or C 1-4 alkyl.
- Z 6 represents a hydrogen atom or C 1-4 alkyl.
- R 3B represents a hydrogen atom, C L ⁇ 6 alkyl, C L ⁇ 6 alkoxy, C L ⁇ 6 alkyl thio, nitro, halogen, triflate Ruo Russia methyl, triflumizole Ruo b methoxy, hydroxyl or hydroxymethyl,
- n and t each independently represent an integer of 1 to 4.
- R 2 and R 3 are Binds only the 1 and 2 positions of
- the present invention relates to a therapeutic and / or Z-prophylactic agent for cancer comprising a sulfonamide or a phorpoamide derivative or a non-toxic salt thereof represented by the following formula:
- Z 5 is a 5- to 7-membered heterocyclic ring having one or two oxygen, sulfur or nitrogen atoms (1 to 5 R 5B groups (a plurality of R 5B groups are independently a hydrogen atom, Alkyl, Cl-6 alkoxy, Cl-6 alkylthio, nitro, halogen, trifluoromethyl, trifluoromethoxy or a hydroxyl group.). Further, the following compounds are more preferable.
- R 1A is hydroxy or C;! -4 alkoxy group
- R 2 A is a hydrogen atom
- R 3A and R 4A are each independently any of a C 1-4 alkyl group or a halogen atom
- R 5 A is a hydrogen atom
- Z 2 is a hydrogen atom
- Z 4 is SO 2 ,
- R 5 B groups are independently hydrogen atoms, C 1 to 6 alkyls, C 1 to 6 alkoxy, C 1 to 6 alkylthio, nitro, halogen, trifluoromethyl , Trifluoromethoxy or a hydroxyl group.
- R 2B is Z 7 - C 1 to 4 alkylene (. Wherein, R 7 is representative of the ⁇ ) is, R 3 B is triflate Ruo Russia methyl group,
- R 4B is C 1-8 alkyl
- the present inventors have now reported that, among PGs, an antagonist of the EP1 receptor, a subtype of the PGE2 receptor, suppresses colonic mucosal abnormal crypts and intestinal polyps formation to a similar extent to COX2 inhibitors
- the present invention was found to have an effect, and the present invention was completed.
- EP1 receptors are responsible for abnormal mucosal crypts and intestinal polyps in the colon It became clear at the same time.
- EP 1 receptor has been known to be involved in pain, fever, and diuresis, and it has been known that antagonizing EP 1 receptor is effective in treating analgesia, antipyretic, and frequent urination Is involved in the formation of abnormal crypts in the large intestinal mucosa and polyp formation in the intestine.
- cancer will occur by the expression of (: ⁇ ⁇ ⁇ 2? 0 E2, so not only intestinal cancer but also stomach cancer, breast cancer, uterine cancer, lung cancer, bladder cancer It is thought that it is also effective for the treatment such as and Z or prevention.
- the compound of the present invention a non-toxic salt thereof, an acid addition salt, a cyclodextrin inclusion compound or a hydrate thereof for the above-mentioned purpose, the compound is usually used in an oral or parenteral form, systemically or locally Is administered.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc. However, it is usually administered orally once to several times a day, in the range of 1 Omg to 100 mg per adult per day, or 0.1 lm per adult per day.
- Parenteral administration preferably intravenous in the range of g to 100 mg once or several times daily or sustained intravenously in the range of 1 to 24 hours daily Is administered.
- a dose smaller than the above dose may be sufficient, or may be required outside the range.
- Solid preparations for oral administration include tablets, pills, capsules, powders, granules and the like.
- Capsules include hard capsules and soft capsules.
- the one or more active substances may be as such or excipients (such as lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (such as hydroxypropylcellulose, polyester). Mixed with vinylpyrrolidone, magnesium metasilicate aluminate, etc.), disintegrant (calcium fiber glycolate, etc.), lubricant (magnesium stearate, etc.), stabilizer, dissolution aid (glutamic acid, aspartic acid, etc.) It is formulated and used in the usual manner.
- excipients such as lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- binders such as hydroxypropylcellulose, polyester
- disintegrant calcium fiber glycolate, etc.
- lubricant magnesium stearate, etc.
- stabilizer dissolution aid
- a coating agent sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose sulfate, etc.
- a coating agent such as gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose sulfate, etc.
- capsules of absorbable materials such as gelatin.
- Liquid preparations for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like.
- one or more of the active substances may be converted to a commonly used diluent (purified water, ethanol Or a mixture of them).
- the liquid preparation may contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffer and the like.
- Injections for parenteral administration include solutions, suspensions, emulsions, and solid injections which are used by dissolving or suspending in a solvent before use. Injectables are used by dissolving, suspending or emulsifying one or more active substances in a solvent.
- the solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol and the like, and combinations thereof are used.
- this injection may contain a stabilizer, a solubilizing agent (glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, and the like. Good. They are prepared by sterilization or aseptic processing in the final step. In addition, a sterile solid preparation, for example, a lyophilized product, can be manufactured and dissolved in sterile distilled water for injection or other solvents before use.
- compositions for parenteral administration include topical solutions, ointments, salves, inhalants, sprays, suppositories and vaginal preparations containing one or more active substances and prescribed in a conventional manner. Pessaries etc. are included.
- Sprays may contain a buffering agent other than commonly used diluents, such as sodium bisulfite, to give isotonicity, for example, isotonic agents such as sodium chloride, sodium citrate or citric acid. It may be contained.
- a buffering agent other than commonly used diluents, such as sodium bisulfite, to give isotonicity, for example, isotonic agents such as sodium chloride, sodium citrate or citric acid. It may be contained.
- Methods for producing spray agents are described in detail, for example, in U.S. Pat. Nos. 2,868,691 and 3,095,355. BEST MODE FOR CARRYING OUT THE INVENTION
- compound A which is one EP1 antagonist, is a compound described in Example 2 (C) of EP 878465.
- the compound B which is another EP1 agonite, is a compound described in Example 18 (94) of WO98Z27053.
- Experimental Example 1 EP1 antagonist in mice induces azoxymethane and suppresses colonic mucosal abnormal crypt formation
- test compound was mixed with a powdered feed (AIN_76A, manufactured by Bio-Serv) and administered as a final feed at a final concentration of 250, 500, or 100 Oppm.
- the test compound administration groups were a group from week 0 (simultaneous administration group) and a group from day 17 (group after AOM treatment). Controls received only powdered feed.
- Necropsy was performed at 5 weeks, and the appearance of abnormal crypts in the large intestine was observed. For observation, abnormal crypt foci and the number of abnormal crypts were measured using a 5 ⁇ binocular microscope. The results are shown in Tables 1 and 2 below.
- Min mice Six-week-old Min mice (spontaneously developing polyps in the intestine) were used as 10 cases per group.
- the drug was mixed with a powdered feed (AIN-76A, Bio-Serv) to give a final concentration of 500 ppm, and the mixture was administered as a feed. Controls include powder Only the feed was allowed free access.
- Necropsy was performed at 7 weeks, and the number of polyps in the small intestine (duodenum, jejunum, ileum) and large intestine was observed. For observation, a 5x binocular microscope was used, and polyps with a diameter of 0.2 mm or more were measured. The results are shown in Table 3 below. Table 3: Inhibitory effect of compound A on intestinal polyp development in Min mice
- Control compound A 500 ppm
- the following compounds were mixed by an ordinary method, granulated, and filled in No. 2 hard capsule to obtain 100 capsules containing 10 Omg of the active ingredient in one capsule.
- the following compounds were mixed by a conventional method, granulated, and tableted to obtain a bare tablet containing 10 Omg of the active ingredient in one tablet, followed by coating to obtain 100 film-coated tablets.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44314/00A AU4431400A (en) | 1999-05-12 | 2000-05-11 | Anticancer agents containing ep1 antagonists as the active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/131195 | 1999-05-12 | ||
JP13119599 | 1999-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000069465A1 true WO2000069465A1 (fr) | 2000-11-23 |
Family
ID=15052259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003028 WO2000069465A1 (fr) | 1999-05-12 | 2000-05-11 | Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4431400A (ja) |
WO (1) | WO2000069465A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072145A1 (fr) * | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif |
WO2002072564A1 (fr) * | 2001-03-12 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production |
EP1370266A1 (en) * | 2001-03-13 | 2003-12-17 | AstraZeneca AB | Method of treatment |
US7084139B2 (en) | 2001-06-08 | 2006-08-01 | Smithkline Beecham Corporation | Pyrrolidin-2-one derivatives as inhibitors of factor Xa |
US7186717B2 (en) | 2001-06-08 | 2007-03-06 | Smithkline Beecham Corporation | Pyrrolidine derivatives as Factor Xa inhibitors |
US7235690B2 (en) | 2001-04-28 | 2007-06-26 | Sanofi-Aventis Deutschland Gmbh | Anthranilamides and methods of their use |
WO2008018544A1 (fr) | 2006-08-10 | 2008-02-14 | Astellas Pharma Inc. | Composé de sulfonamide ou son sel |
WO2008099907A1 (ja) | 2007-02-16 | 2008-08-21 | Ono Pharmaceutical Co., Ltd. | 尿排出障害治療剤 |
WO2009133863A1 (ja) | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Ep1アゴニストを含有してなる免疫増強剤 |
WO2009157399A1 (ja) | 2008-06-23 | 2009-12-30 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
US7960392B2 (en) | 2008-07-17 | 2011-06-14 | Asahi Kasei Pharma Corporation | Nitrogen-containing heterocyclic compounds |
US7994202B2 (en) | 2008-07-17 | 2011-08-09 | Asahi Kasei Pharma Corporation | Bicyclic nitrogen-containing heterocyclic compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993012075A1 (en) * | 1991-12-10 | 1993-06-24 | Shionogi & Co., Ltd. | Hydroxamic acid derivative based on aromatic sulfonamide |
-
2000
- 2000-05-11 AU AU44314/00A patent/AU4431400A/en not_active Abandoned
- 2000-05-11 WO PCT/JP2000/003028 patent/WO2000069465A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993012075A1 (en) * | 1991-12-10 | 1993-06-24 | Shionogi & Co., Ltd. | Hydroxamic acid derivative based on aromatic sulfonamide |
Non-Patent Citations (2)
Title |
---|
CANCER RES., vol. 59, no. 20, October 1999 (1999-10-01), pages 5093 - 5096 * |
DATABASE CAPLUS ON STN AMERICAN CHEMICAL SOCIETY (COLUMBUS, OHIO, USA); WATANABE KOUJI ET AL.: "Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis", XP002930166 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072564A1 (fr) * | 2001-03-12 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production |
US8088802B2 (en) | 2001-03-12 | 2012-01-03 | Ono Pharmaceutical Co., Ltd. | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
EP1612208A3 (en) * | 2001-03-12 | 2006-12-06 | Ono Pharmaceutical Co., Ltd. | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
CN1294126C (zh) * | 2001-03-12 | 2007-01-10 | 小野药品工业株式会社 | N-苯基芳基磺酰胺化合物、包括该化合物作为活性成分的药物组合物、该化合物的合成中间体及其制备方法 |
US7629369B2 (en) | 2001-03-12 | 2009-12-08 | Ono Pharmaceuticals Co., Ltd. | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
US7235667B2 (en) | 2001-03-12 | 2007-06-26 | Ono Pharmaceutical Co., Ltd. | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
EP1370266A1 (en) * | 2001-03-13 | 2003-12-17 | AstraZeneca AB | Method of treatment |
WO2002072145A1 (fr) * | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif |
EP1369129A4 (en) * | 2001-03-14 | 2005-08-03 | Ono Pharmaceutical Co | ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT |
US7335776B2 (en) | 2001-03-14 | 2008-02-26 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing EP1 antagonist as the active ingredient |
US7235690B2 (en) | 2001-04-28 | 2007-06-26 | Sanofi-Aventis Deutschland Gmbh | Anthranilamides and methods of their use |
US7326785B2 (en) | 2001-06-08 | 2008-02-05 | Glaxo Group Limited | Pyrrolidine derivatives as factor XA inhibitors |
US7226929B2 (en) | 2001-06-08 | 2007-06-05 | Smithkline Beecham Corporation | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
US7429587B2 (en) | 2001-06-08 | 2008-09-30 | Glaxo Group Limited | Pyrrolidine derivatives as factor Xa inhibitors |
US7517879B2 (en) | 2001-06-08 | 2009-04-14 | Glaxo Group Limited | Pyrrolidine derivatives as factor Xa inhibitors |
US7282497B2 (en) | 2001-06-08 | 2007-10-16 | Glaxo Group Limited | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
US7186717B2 (en) | 2001-06-08 | 2007-03-06 | Smithkline Beecham Corporation | Pyrrolidine derivatives as Factor Xa inhibitors |
US7084139B2 (en) | 2001-06-08 | 2006-08-01 | Smithkline Beecham Corporation | Pyrrolidin-2-one derivatives as inhibitors of factor Xa |
US7973078B2 (en) | 2006-08-10 | 2011-07-05 | Astellas Pharma Inc. | Sulfonamide compound or salt thereof |
WO2008018544A1 (fr) | 2006-08-10 | 2008-02-14 | Astellas Pharma Inc. | Composé de sulfonamide ou son sel |
WO2008099907A1 (ja) | 2007-02-16 | 2008-08-21 | Ono Pharmaceutical Co., Ltd. | 尿排出障害治療剤 |
WO2009133863A1 (ja) | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Ep1アゴニストを含有してなる免疫増強剤 |
WO2009157399A1 (ja) | 2008-06-23 | 2009-12-30 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
US8314240B2 (en) | 2008-06-23 | 2012-11-20 | Astellas Pharma Inc. | Sulfonamide compounds or salts thereof |
US7960392B2 (en) | 2008-07-17 | 2011-06-14 | Asahi Kasei Pharma Corporation | Nitrogen-containing heterocyclic compounds |
US7994202B2 (en) | 2008-07-17 | 2011-08-09 | Asahi Kasei Pharma Corporation | Bicyclic nitrogen-containing heterocyclic compounds |
Also Published As
Publication number | Publication date |
---|---|
AU4431400A (en) | 2000-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201136916A (en) | New uses | |
TWI286476B (en) | Combination of cytochrome P450 dependent protease inhibitors | |
WO2000069465A1 (fr) | Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif | |
WO1995014384A1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
JPWO2003043655A1 (ja) | 頻尿の治療剤 | |
US20060217431A1 (en) | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | |
EP2175861B1 (en) | Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 | |
JP5302900B2 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
TWI336254B (en) | Pharmaceutical composition for treating abdominal discomfort | |
JP2010065060A (ja) | 心不全処置のための複合治療 | |
CA2084568A1 (en) | Medicaments for treating inflammatory conditions or analgesia | |
WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
TW415843B (en) | Anti-cancer pharmaceutical compositions comprising a diaminotrifluoromethylpyridine derivatives or the pharmaceutically acceptable salts thereof | |
EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
JP2011526266A (ja) | 消化管の炎症状態の処置を目的とするオキサゾリジノン類 | |
US20060128810A1 (en) | Remedies for allergic diseases | |
WO2004043491A1 (ja) | 脊柱管狭窄症治療剤 | |
JP2008520679A (ja) | うっ血性心不全の処置のためにpdevインヒビターを使用する方法 | |
JP2006021998A (ja) | Ep2アゴニストを有効成分とする月経困難症治療剤 | |
JPH0653678B2 (ja) | アレルギ−性疾患治療剤 | |
TW575421B (en) | Medicine for coronary artery disease | |
US7842702B2 (en) | Treatment for irritable bowel syndrome | |
JP2007536208A (ja) | 腎疾患を処置するためのプロスタグランジンe2レセプターアンタゴニストおよびレニン−アンジオテンシン系インヒビターの組み合わせ | |
JP4677705B2 (ja) | 頭痛の予防および/または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 617925 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |